Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology
- PMID: 29391233
- DOI: 10.1016/j.phrs.2018.01.011
Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology
Abstract
Qijian mixture, a new traditional Chinese medicine (TCM) formula comprising of Astragalus membranaceus, Ramulus euonymi, Coptis chinensis and Pueraria lobata, was designed to ameliorate the type 2 diabetes (T2D), and its safety and efficacy were evaluated in the research by metabonomics, gut microbiota and system pharmacology. To study the hypoglycemic effect of Qijian mixture, male KKay mice (28-30 g, 8-9 week) and C57/BL6 mice (18-19 g, 8-9 week) were used. Thirty KKay diabetic mice were randomly distributed into 5 groups, abbreviated as Model group (Model), Low Qijian Mixture group (QJM(L)), High Qijian Mixture group (QJM(H)), Chinese Medicine (Gegen Qinlian Decoction) Positive group (GGQL), and Western Medicine (Metformin hydrochloride) Positive group (Metformin). C57/BL6 was considered as the healthy control group (Control). Moreover, a system pharmacology approach was utilized to assess the physiological targets involved in the action of Qijian mixture. There was no adverse drug reaction of Qijian mixture in the acute toxicity study and HE result, and, compared with Model group, Qijian mixture could modulate blood glycemic level safely and effectively. Qijian Mixture was lesser effective than metformin hydrochloride; however, both showed similar hypoglycemic trend. Based on 1H NMR based metabonomics study, the profoundly altered metabolites in Qijian mixture treatment group were identified. Qijian mixture-related 55 proteins and 4 signaling pathways, including galactose metabolism, valine, leucine and isoleucine degradation metabolism, aminoacyl-tRNA biosynthesis metabolism and alanine, aspartate and glutamate metabolism pathways, were explored. The PCoA analysis of gut microbiota revealed that Qijian mixture treatment profoundly enriched bacteroidetes. In addition, the system pharmacology paradigm revealed that Qijian mixture acted through TP53, AKT1 and PPARA proteins. It was concluded that Qijian mixture effectively alleviated T2D, and this effect was linked with the altered features of the metabolite profiles and the gut microbiota.
Keywords: Gut microbiota; Mechanism of action; Metabonomics; Molecular targets; System pharmacology; Type 2 diabetes.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Study on the mechanism of Gegen Qinlian Decoction for treating type II diabetes mellitus by integrating network pharmacology and pharmacological evaluation.J Ethnopharmacol. 2020 Nov 15;262:113129. doi: 10.1016/j.jep.2020.113129. Epub 2020 Jul 28. J Ethnopharmacol. 2020. PMID: 32730886
-
BuZangTongLuo decoction improved hindlimb ischemia by activating angiogenesis and regulating gut microbiota in diabetic mice.J Ethnopharmacol. 2020 Feb 10;248:112330. doi: 10.1016/j.jep.2019.112330. Epub 2019 Oct 22. J Ethnopharmacol. 2020. PMID: 31654796
-
Metabolomics-based evidence of the hypoglycemic effect of Ge-Gen-Jiao-Tai-Wan in type 2 diabetic rats via UHPLC-QTOF/MS analysis.J Ethnopharmacol. 2018 Jun 12;219:299-318. doi: 10.1016/j.jep.2018.03.026. Epub 2018 Mar 23. J Ethnopharmacol. 2018. PMID: 29580854
-
Efficacy and safety of Gegen Qinlian decoction for normalizing hyperglycemia in diabetic patients: A systematic review and meta-analysis of randomized clinical trials.Complement Ther Med. 2017 Aug;33:6-13. doi: 10.1016/j.ctim.2017.05.004. Epub 2017 May 26. Complement Ther Med. 2017. PMID: 28735827 Review.
-
New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes.Drug Des Devel Ther. 2021 Nov 30;15:4849-4863. doi: 10.2147/DDDT.S334325. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34876807 Free PMC article. Review.
Cited by
-
Characteristics of elderly diabetes patients: focus on clinical manifestation, pathogenic mechanism, and the role of traditional Chinese medicine.Front Pharmacol. 2024 Jan 11;14:1339744. doi: 10.3389/fphar.2023.1339744. eCollection 2023. Front Pharmacol. 2024. PMID: 38273819 Free PMC article. Review.
-
Exploring global research status and trends in anti-obesity effects of traditional Chinese medicine through intestinal microbiota: a bibliometric study.Front Cell Infect Microbiol. 2023 Nov 16;13:1271473. doi: 10.3389/fcimb.2023.1271473. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 38045760 Free PMC article.
-
Gut Microbiota Combined with Serum Metabolomics to Investigate the Hypoglycemic Effect of Actinidia arguta Leaves.Nutrients. 2023 Sep 23;15(19):4115. doi: 10.3390/nu15194115. Nutrients. 2023. PMID: 37836402 Free PMC article.
-
Modular characteristics and mechanism of action of herbs for type 2 diabetes treatment in Chinese medicine.Heliyon. 2023 Sep 16;9(9):e20106. doi: 10.1016/j.heliyon.2023.e20106. eCollection 2023 Sep. Heliyon. 2023. PMID: 37809579 Free PMC article.
-
Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review.Front Immunol. 2023 Aug 10;14:1243834. doi: 10.3389/fimmu.2023.1243834. eCollection 2023. Front Immunol. 2023. PMID: 37638043 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
